Safety and efficacy of nonsteroidal anti-inflammatory drugs – acemetacin from the neurologist point of view Review article
Article Sidebar
Published:
Jun 30, 2017
Keywords:
nonsteroidal anti-inflammatory drugs, pain, acemetacin
Main Article Content
Abstract
There are various drugs with different mechanisms of action used in pain management. Despite the adverse effects from the gastrointestinal tract, circulatory system or kidneys, nonsteroidal anti-inflammatory drugs (NSAIDs) are still the first-choice drugs in the pain management of osteoarticular system. Safety and efficacy of treatment are the basis for choosing a proper NSAID drug. Acemetacin due to its pharmacological properties may be the drug of choice in a particular group of patients.
Article Details
How to Cite
Białecka, M. (2017). Safety and efficacy of nonsteroidal anti-inflammatory drugs – acemetacin from the neurologist point of view. Medycyna Faktow (J EBM), 10(2(35), 120-123. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2152
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Jacobi H., Dell H.D.: On the pharmacodynamics of acemetacin. Arzneimittelforschung. 1980; 30(8A): 1348-1362.
2. Bori-Segura G., Herrera L.E., Olguín-Uribe J.: Efficacy and tolerability of acemetacin, a non-steroidal anti-inflammatory drug, in Mexican patients: Result of the ETAPAM study. Proc. West. Pharmacol. Soc. 2002; 45: 104-107.
3. Chávez-Piña A.E., McKnight W., Dicay M. et al.: Mechanism underlying the anti-inflammatory activity and gastric safety of acemetacin. Br. J. Pharmacol. 2007; 152(6): 930-938.
4. Kirchner T., Aparicio B., Argentieri D.C. et al.: Effects of tepoxalin, a dual inhibitor of cyclooxygenase/5-lipoxygenase, on events associated with NSAID-induced gastrointestinal inflammation. Prostaglandins Leukot. Essent. Fatty Acids 1997; 56: 417-423.
5. Leeb B.F., Bucsi L., Keszthelyi B. et al.: Treatment of osteoarthritis of the knee joint. Efficacy and tolerance to acemetacin slow release in comparison to celecoxib. Orthopade 2004; 33: 1032-1041.
6. Ortiz M.I., Ponce-Monter H., Fernández-Martínez E. et al.: Evaluation of the interaction between acemetacin and opioids on the hargreaves model of thermal hyperalgesia. Pharmacol. Biochem. Behav. 2007; 88(1): 47-54.
7. Dejaco C., Duftner C., Schirmer M.: Lack of influence of body mass index on efficacy and tolerance of acemetacin in short-term treatment of musculoskeletal diseases. Rheumatol. Int. 2007; 27(4): 351-355.
2. Bori-Segura G., Herrera L.E., Olguín-Uribe J.: Efficacy and tolerability of acemetacin, a non-steroidal anti-inflammatory drug, in Mexican patients: Result of the ETAPAM study. Proc. West. Pharmacol. Soc. 2002; 45: 104-107.
3. Chávez-Piña A.E., McKnight W., Dicay M. et al.: Mechanism underlying the anti-inflammatory activity and gastric safety of acemetacin. Br. J. Pharmacol. 2007; 152(6): 930-938.
4. Kirchner T., Aparicio B., Argentieri D.C. et al.: Effects of tepoxalin, a dual inhibitor of cyclooxygenase/5-lipoxygenase, on events associated with NSAID-induced gastrointestinal inflammation. Prostaglandins Leukot. Essent. Fatty Acids 1997; 56: 417-423.
5. Leeb B.F., Bucsi L., Keszthelyi B. et al.: Treatment of osteoarthritis of the knee joint. Efficacy and tolerance to acemetacin slow release in comparison to celecoxib. Orthopade 2004; 33: 1032-1041.
6. Ortiz M.I., Ponce-Monter H., Fernández-Martínez E. et al.: Evaluation of the interaction between acemetacin and opioids on the hargreaves model of thermal hyperalgesia. Pharmacol. Biochem. Behav. 2007; 88(1): 47-54.
7. Dejaco C., Duftner C., Schirmer M.: Lack of influence of body mass index on efficacy and tolerance of acemetacin in short-term treatment of musculoskeletal diseases. Rheumatol. Int. 2007; 27(4): 351-355.